Daily pill aims to keep aggressive brain tumors at bay

NCT ID NCT06809322

Recruiting now Disease control Sponsor: European Organisation for Research and Treatment of Cancer - EORTC Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a daily pill called vorasidenib can help keep a specific type of brain tumor from growing back after patients finish their initial chemotherapy and radiation. About 468 adults with IDH-mutant grade 2 or 3 astrocytoma will take either the real drug or a placebo pill daily to see which group stays progression-free longer. The goal is to see if this maintenance therapy can effectively control the disease over time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AOU Citta della Salute e della Scienza di Torino
NOT_YET_RECRUITING

Torino, Italy
Academisch Ziekenhuis Maastricht
RECRUITING

Maastricht, Netherlands
Amsterdam UMC location VUMC
NOT_YET_RECRUITING

Amsterdam, Netherlands
Assistance Publique Hopitaux de Paris APHP - Sorbonne
NOT_YET_RECRUITING

Paris, France
Bellaria Hospital, IRCCS Istituto delle Scienze Neurologiche - AUSL di Bologna
NOT_YET_RECRUITING

Bologna, Italy
CHU Lyon - Hopital neurologique Pierre Wertheimer
NOT_YET_RECRUITING

Lyon, France
Clatterbridge Cancer Centre
NOT_YET_RECRUITING

Metropolitan Borough of Wirral, United Kingdom
Erasmus MC
RECRUITING

Rotterdam, Netherlands
Ghent University Hospital
RECRUITING

Ghent, Belgium
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, Spain
Hospital de Sant Pau i La Santa Creu
NOT_YET_RECRUITING

Barcelona, Spain
Kepler University Hospital - Neuromed campus
RECRUITING

Linz, Austria
Mannheim University Hospital
RECRUITING

Mannheim, Germany
Marseille APHM
NOT_YET_RECRUITING

Marseille, France
Masaryk Memorial Cancer Institute
NOT_YET_RECRUITING

Brno, Czechia
Medical University of Innsbruck
NOT_YET_RECRUITING

Innsbruck, Austria
Medical University of Vienna
RECRUITING

Vienna, Austria
NNeurology department heidelberg
NOT_YET_RECRUITING

Heidelberg, Germany
Oncopole Claudius Regaud, IUCT-Oncopole
NOT_YET_RECRUITING

Toulouse, France
Queen Elizabeth Hospital Birmingham
NOT_YET_RECRUITING

Birmingham, United Kingdom
Royal Marsden Hospital
NOT_YET_RECRUITING

Surrey Quays, United Kingdom
Sapienza University
NOT_YET_RECRUITING

Roma, Italy
The Christie NHS Foundation Trust
NOT_YET_RECRUITING

Manchester, United Kingdom
U.Z. Leuven - Campus Gasthuisberg
RECRUITING

Leuven, Belgium
Universitaetsklinikum Regensburg
NOT_YET_RECRUITING

Regensburg, Germany
Universitair Ziekenhuis Brussel
RECRUITING

Brussels, Belgium
Universitary hospital Bordeaux France
NOT_YET_RECRUITING

Bordeaux, France
Universitaskliniken Bonn
NOT_YET_RECRUITING

Bonn, Germany
University Hospital Basel
NOT_YET_RECRUITING

Basel, Switzerland
University Hospital Frankfurt -Senckenberg Institute of Neurooncology
NOT_YET_RECRUITING

Frankfurt, Germany
University Hospital Zurich
NOT_YET_RECRUITING

Zurich, Switzerland
Vall de Hebron Hospital
RECRUITING

Barcelona, Spain
Veneto Institute of Oncology
NOT_YET_RECRUITING

Padova, Italy

Conditions

Explore the condition pages connected to this study.

IDH-MUTANT GRADE 2 OR 3 ASTROCYTOMA